Active substance
Domperidone
- SFDA 15
- Health Canada 11
- NHS prices 3
- Safety 5
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| AMISTOP 5MG-5ML SUSPENSION | 0.1 % | Suspension · Oral use | 1 Bottle | SAR 15.40 | Generic · Prescription | DEEF PHARMACEUTICAL INDUSTRIES | Valid |
| DOMPY 0.1% ORAL SUSPENTION | 0.1 mg/ml | Suspension · Oral use | 1 Bottle | SAR 19.00 | Generic · Prescription | Jamjoom Pharmaceuticals Factory Company | Valid |
| DOMPY 10MG TABLET | 10 mg | Tablet · Oral use | 30 Blister | SAR 16.25 | Generic · Prescription | Jamjoom Pharmaceuticals Factory Company | Valid |
| MODODOM 10MG F.C. TABLETS | 10 mg | Film-coated tablet · Oral use | 20 Blister | SAR 7.45 | Generic · Prescription | Gulf Pharmaceutical Industries (Julphar) | Valid |
| MOTILIUM TAB 10MG | 10 mg | Film-coated tablet · Oral use | 30 Blister | SAR 17.10 | NCE · Prescription | Johnson & Johnson Consumer NV/SA | Valid |
| MOTILONE 10MG F.C.TABLET | 10 mg | Coated tablet · Oral use | 20 Blister | SAR 7.45 | Generic · Prescription | National Pharmaceutical Industries Co. (SAOG) | Valid |
| Motilone | 10 mg | Coated tablet · Oral use | 1000 Blister | SAR 244.80 | Generic · Prescription | National Pharmaceutical Industries Co. (SAOG) | Valid |
| PROKININ 10MG F-C TABLETS | 10 mg | Film-coated tablet · Oral use | 30 Blister | SAR 16.25 | Generic · Prescription | Tabuk Pharmaceutical Manufacturing Company | Valid |
| PROKININ 5MG-5ML SUSPENSION | 0.1 % | Oral suspension · Oral use | 1 Bottle | SAR 17.10 | Generic · Prescription | Tabuk Pharmaceutical Manufacturing Company | Valid |
| NAUSIDOM 10 mg Tablet | 10 mg | Film-coated tablet · Oral use | 30 Blister | SAR 11.20 | Generic · Prescription | NEOPHARMA | Suspended |
| MODODOM 1MG-1ML SUSPENSION | 0.1 % | Oral suspension · Oral use | 1 Bottle | SAR 8.40 | Generic · Prescription | Gulf Pharmaceutical Industries (Julphar) | Withdrawn by MAH · Not Marketed |
| MOTILIUM SUPP 10MG FOR INFANT | 10 mg | Suppository · Rectal use | 6 Blister | SAR 11.25 | NCE · Prescription | JANSSEN-CILAG | Withdrawn by MAH · Not Marketed |
| MOTILIUM SUPP 30MG FOR CHILD. | 30 mg | Suppository · Rectal use | 6 Blister | SAR 17.60 | NCE · Prescription | JANSSEN-CILAG | Withdrawn by MAH · Not Marketed |
| MOTILIUM SUPP 60MG FOR ADULT | 60 mg | Suppository · Rectal use | 6 Blister | SAR 21.75 | NCE · Prescription | JANSSEN-CILAG | Withdrawn by MAH · Not Marketed |
| MOTILIUM SYRUP 0.1% | 0.1 % | Syrup · Oral use | 1 Bottle | SAR 20.00 | NCE · Prescription | JANSSEN PHARMACEUTICA N.V | Withdrawn by MAH · Not Marketed |
Indications — CHI Daman Drug Formulary
DYSPEPSIA; GASTROESOPHAGEAL REFLUX DISEASE (GERD); MIGRAINE/ HEADACHE; NAUSEA AND VOMITING IN PREGNANCY; PEPTIC ULCER; VERTIGO - MOTION SICKNESS
Canada Canada — marketed products (Health Canada)
| Brand | DIN | Strength | Form · route | Company |
|---|---|---|---|---|
| BIO-DOMPERIDONE | 02445034 | 10 MG | TABLET · ORAL | BIOMED PHARMA |
| DOMPERIDONE | 02238341 | 10 MG | TABLET · ORAL | SIVEM PHARMACEUTICALS ULC |
| DOMPERIDONE | 02350440 | 10 MG | TABLET · ORAL | SANIS HEALTH INC |
| JAMP DOMPERIDONE TABLETS | 02543435 | 10 MG | TABLET · ORAL | JAMP PHARMA CORPORATION |
| JAMP-DOMPERIDONE | 02369206 | 10 MG | TABLET · ORAL | JAMP PHARMA CORPORATION |
| MAR-DOMPERIDONE | 02403870 | 10 MG | TABLET · ORAL | MARCAN PHARMACEUTICALS INC |
| NRA-DOMPERIDONE | 02561905 | 10 MG | TABLET · ORAL | NORA PHARMA INC |
| PRO-DOMPERIDONE | 02236857 | 10 MG | TABLET · ORAL | PRO DOC LIMITEE |
| PRZ-DOMPERIDONE | 02462834 | 10 MG | TABLET · ORAL | PHARMARIS CANADA INC |
| TARO-DOMPERIDONE | 02268078 | 10 MG | TABLET · ORAL | SUN PHARMA CANADA INC |
| TEVA-DOMPERIDONE | 01912070 | 10 MG | TABLET · ORAL | TEVA CANADA LIMITED |
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| NHS Drug Tariff | Domperidone 10mg tablets | £0.95 | 30 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Domperidone 10mg tablets | £3.17 | 100 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Domperidone 1mg/ml oral suspension sugar free | £49.32 | 200 ml | 1 Oct 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
Safety signals and safety-related labeling changes
- MHRA 21 Jul 2026 Domperidone: new contraindication in patients with phaeochromocytoma due to the risk of severe hypertension
The product information has been updated for all domperidone products, to include a contraindication for patients with confirmed or suspected phaeochromocytoma (a rare tumour of the adrenal gland), due to the risk of episodes of severe hypertension. - EMA PRAC 31 Oct 2024 PRAC signal: Hypertension in patients with a phaeochromocytoma
Action for MAH: update of the product information: No - MHRA 11 Dec 2014 Domperidone: no longer available without prescription
People now need to have a medical assessment before taking domperidone to determine if it is suitable for them due to the risk of cardiac side effects. - MHRA 11 Dec 2014 Domperidone: risks of cardiac side effects
Indication restricted to nausea and vomiting, new contraindications, and reduced dose and duration of use. - EMA PRAC 7 Feb 2013 PRAC signal: Cardiotoxicity
Action for MAH: update of the product information: No
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.